The MDxHealth downgrade by Craig-Hallum on October 16, 2026, followed a revenue shortfall and the suspension of the diagnostics company’s full-year revenue guidance. The brokerage cut its rating from Buy to Hold, citing revenue challenges, uncertainty over the outlook and liquidity concerns.
Key Takeaways
- Preliminary third-quarter revenue from continuing operations was flat from a year earlier.
- MDxHealth suspended its $110–115 million full-year 2026 revenue guidance.
- Management linked the shortfall to unexpected sales-force turnover after discontinuing Resolve mdx.
Table of Contents
- MDxHealth downgrade follows a stalled revenue quarter
- Sales turnover disrupts execution
- Liquidity concerns remain separate from cash runway
- Conclusion
MDxHealth downgrade follows a stalled revenue quarter
MDxHealth’s preliminary third-quarter revenue announcement, issued October 15, put revenue from continuing operations at approximately $22.7 million for the quarter ended September 30, 2026. That matched the comparable 2025 figure, which was re-presented to exclude Resolve mdx as a discontinued operation.
The flat year-over-year result fell short of management’s expectations. Rather than provide a revised annual range, the company suspended its previous full-year revenue guidance of $110–115 million, leaving investors without an updated management target.
The figures remain preliminary and unaudited. MDxHealth said they are subject to its quarter-end close and review procedures and could differ materially from final results.
| Item | Details |
|---|---|
| Tissue-based test volume | 11,232 in Q3 2026, down 11% year over year; includes Confirm mdx and GPS mdx. |
| Liquid-based test volume | 11,792 Exo mdx tests in Q3 2026 versus 4,600 Select mdx and Exo mdx tests a year earlier. |
| Cash and cash equivalents | Approximately $31.7 million as of September 30, 2026. |
Sales turnover disrupts execution
Chief Executive Michael K. McGarrity said unexpected sales-force turnover followed the discontinuation of Resolve mdx. He attributed the departures to aggressive recruiter targeting and said the disruption had undermined the process supporting the company’s forecasts.
Management is working to strengthen affected sales territories. McGarrity said the company did not believe the disruption reflected a change in customer relationships, underlying clinical demand or its long-term opportunity. His expectation of a return to growth is a management outlook, not an achieved recovery.
Test volumes showed different trends across the portfolio. Tissue-based testing declined, while the liquid-based comparison included a change in product mix following the September 2025 acquisition of Exo mdx.
Liquidity concerns remain separate from cash runway
Craig-Hallum’s liquidity concerns add a financing dimension to the operating setback. MDxHealth disclosed its quarter-end cash balance, but the preliminary announcement did not provide a cash-runway estimate. The balance alone therefore does not establish how long the company can fund operations or whether it will need additional capital.
The next scheduled update is November 12, when MDxHealth plans to publish full third-quarter results and hold its earnings call. Management said it would provide more detail on corrective actions and progress at that time.
Conclusion
The downgrade follows an operating setback that has left MDxHealth without a full-year revenue target. The November 12 results and earnings call are the next confirmed opportunity to assess final quarterly figures and management’s progress in rebuilding sales execution.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
